Anthera Pharmaceuticals Inc. (ANTH) Upgraded at Zacks Investment Research
Anthera Pharmaceuticals Inc. (NASDAQ:ANTH) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Tuesday.
According to Zacks, “Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products to treat serious illnesses, including cardiovascular and autoimmune diseases. The Company’s clinical-stage programs include one Phase 3 ready program, A-002, and two Phase 2 clinical programs, A-623 and A-001. A-002 and A-001 inhibit a novel enzyme target known as secretory phospholipase A2, or sPLA2. Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome, as well as chronic diseases such as stable coronary artery disease. A-623 targets elevated levels of B-lymphocyte stimulator, or BLyS (also known as BAFF), which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis, multiple sclerosis, Sjögren’s Syndrome, Graves’ Disease and others. Anthera Pharmaceuticals, Inc. is headquartered in Hayward, California. “
Several other brokerages also recently weighed in on ANTH. HC Wainwright started coverage on Anthera Pharmaceuticals in a report on Friday, July 8th. They issued a “buy” rating and a $10.00 price target for the company. FBR & Co reiterated a “hold” rating on shares of Anthera Pharmaceuticals in a report on Monday, June 20th. Finally, Jefferies Group reiterated a “buy” rating on shares of Anthera Pharmaceuticals in a report on Thursday, June 30th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $8.70.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/11/anthera-pharmaceuticals-inc-anth-upgraded-at-zacks-investment-research.html
Anthera Pharmaceuticals (NASDAQ:ANTH) traded down 2.80% on Tuesday, reaching $3.12. The company had a trading volume of 244,808 shares. The firm’s market capitalization is $129.25 million. The stock’s 50-day moving average price is $3.10 and its 200 day moving average price is $3.34. Anthera Pharmaceuticals has a 52-week low of $2.28 and a 52-week high of $7.15.
Anthera Pharmaceuticals (NASDAQ:ANTH) last posted its earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.31) by $0.04. Anthera Pharmaceuticals had a negative net margin of 1,273.45% and a negative return on equity of 131.24%. On average, equities analysts anticipate that Anthera Pharmaceuticals will post ($1.37) earnings per share for the current fiscal year.
Hedge funds have recently added to or reduced their stakes in the company. Wexford Capital LP purchased a new stake in Anthera Pharmaceuticals during the first quarter worth approximately $256,000. State Street Corp increased its stake in Anthera Pharmaceuticals by 6.6% in the first quarter. State Street Corp now owns 556,307 shares of the biopharmaceutical company’s stock worth $2,014,000 after buying an additional 34,225 shares during the last quarter. Franklin Resources Inc. increased its stake in Anthera Pharmaceuticals by 17.6% in the first quarter. Franklin Resources Inc. now owns 3,197,712 shares of the biopharmaceutical company’s stock worth $11,576,000 after buying an additional 479,700 shares during the last quarter. Rhumbline Advisers increased its stake in Anthera Pharmaceuticals by 47.4% in the second quarter. Rhumbline Advisers now owns 56,389 shares of the biopharmaceutical company’s stock worth $174,000 after buying an additional 18,135 shares during the last quarter. Finally, FMR LLC increased its stake in Anthera Pharmaceuticals by 17.8% in the second quarter. FMR LLC now owns 3,247,907 shares of the biopharmaceutical company’s stock worth $10,036,000 after buying an additional 490,100 shares during the last quarter. Institutional investors and hedge funds own 55.24% of the company’s stock.
About Anthera Pharmaceuticals
Anthera Pharmaceuticals, Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Anthera Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anthera Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.